Amalgamated Bank Alnylam Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

  • $12.2 Billion
  • Q4 2024

A detailed history of Amalgamated Bank transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 8,484 shares of ALNY stock, worth $2.12 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,484
Previous 8,279 2.48%
Holding current value
$2.12 Million
Previous $2.28 Million 12.34%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025
BUY
$232.27 - $300.43 $47,615 - $61,588
205 Added 2.48%
8,484 $2 Million
Q3 2024

Oct 30, 2024
SELL
$233.81 - $287.01 $17,535 - $21,525
-75 Reduced 0.9%
8,279 $2.28 Million
Q2 2024

Aug 12, 2024
BUY
$143.31 - $247.0 $43,136 - $74,347
301 Added 3.74%
8,354 $2.03 Million
Q1 2024

Apr 23, 2024
SELL
$146.51 - $198.2 $484,362 - $655,249
-3,306 Reduced 29.1%
8,053 $1.2 Million
Q4 2023

Feb 06, 2024
SELL
$151.41 - $196.57 $210,005 - $272,642
-1,387 Reduced 10.88%
11,359 $2.17 Million
Q3 2023

Nov 08, 2023
SELL
$170.77 - $211.65 $68,308 - $84,660
-400 Reduced 3.04%
12,746 $2.26 Million
Q2 2023

Aug 11, 2023
SELL
$185.01 - $212.05 $172,429 - $197,630
-932 Reduced 6.62%
13,146 $2.5 Million
Q1 2023

May 02, 2023
BUY
$182.66 - $235.53 $38,541 - $49,696
211 Added 1.52%
14,078 $2.82 Million
Q4 2022

Feb 10, 2023
BUY
$185.53 - $241.31 $71,800 - $93,386
387 Added 2.87%
13,867 $3.3 Million
Q3 2022

Nov 09, 2022
BUY
$138.54 - $232.0 $29,509 - $49,416
213 Added 1.61%
13,480 $2.7 Million
Q2 2022

Aug 15, 2022
SELL
$120.42 - $169.29 $10,596 - $14,897
-88 Reduced 0.66%
13,267 $1.94 Million
Q1 2022

Jun 30, 2022
BUY
$127.18 - $173.91 $365,896 - $500,339
2,877 Added 27.46%
13,355 $2.18 Million
Q4 2021

Feb 15, 2022
BUY
$159.56 - $209.29 $574,735 - $753,862
3,602 Added 52.39%
10,478 $1.78 Million
Q3 2021

Oct 29, 2021
SELL
$169.75 - $207.73 $181,293 - $221,855
-1,068 Reduced 13.44%
6,876 $1.3 Million
Q2 2021

Aug 16, 2021
BUY
$128.63 - $176.89 $291,218 - $400,478
2,264 Added 39.86%
7,944 $1.35 Million
Q1 2021

May 13, 2021
SELL
$126.83 - $175.69 $42,868 - $59,383
-338 Reduced 5.62%
5,680 $802,000
Q4 2020

Feb 12, 2021
SELL
$122.97 - $147.0 $10,821 - $12,936
-88 Reduced 1.44%
6,018 $782,000
Q3 2020

Oct 30, 2020
SELL
$121.19 - $165.49 $5,211 - $7,116
-43 Reduced 0.7%
6,106 $889,000
Q2 2020

Aug 10, 2020
SELL
$104.21 - $156.44 $2.19 Million - $3.28 Million
-20,994 Reduced 77.35%
6,149 $911,000
Q1 2020

May 13, 2020
SELL
$93.12 - $133.99 $30,822 - $44,350
-331 Reduced 1.2%
27,143 $2.96 Million
Q4 2019

Feb 13, 2020
BUY
$74.51 - $124.23 $112,212 - $187,090
1,506 Added 5.8%
27,474 $3.16 Million
Q3 2019

Nov 13, 2019
BUY
$70.9 - $87.82 $204,759 - $253,624
2,888 Added 12.51%
25,968 $2.09 Million
Q2 2019

Aug 14, 2019
BUY
$65.86 - $92.79 $138,898 - $195,694
2,109 Added 10.06%
23,080 $1.68 Million
Q1 2019

May 15, 2019
BUY
$72.76 - $93.45 $101,936 - $130,923
1,401 Added 7.16%
20,971 $1.96 Million
Q4 2018

Feb 15, 2019
BUY
$62.67 - $88.33 $425,842 - $600,202
6,795 Added 53.19%
19,570 $1.43 Million
Q3 2018

Nov 14, 2018
SELL
$87.52 - $122.67 $669,090 - $937,812
-7,645 Reduced 37.44%
12,775 $1.12 Million
Q2 2018

Jul 18, 2018
BUY
$88.31 - $107.8 $183,684 - $224,224
2,080 Added 11.34%
20,420 $2.01 Million
Q1 2018

May 22, 2018
BUY
$115.92 - $148.54 $142,349 - $182,407
1,228 Added 7.18%
18,340 $2.18 Million
Q4 2017

Feb 13, 2018
BUY
$114.49 - $139.98 $236,994 - $289,758
2,070 Added 13.76%
17,112 $2.17 Million
Q3 2017

Nov 09, 2017
BUY
$72.53 - $118.27 $1.09 Million - $1.78 Million
15,042
15,042 $1.77 Million

Others Institutions Holding ALNY

# of Institutions
666
Shares Held
112M
Call Options Held
839K
Put Options Held
771K
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email